Impact of biologic therapies on quality of life of psoriasis patients: results from the British Association of Dermatologists Biologic Interventions Register

Research output: Chapter in Book/Report/Conference proceedingConference contribution

  • External authors:
  • Kathleen Mcelhone
  • Catherine H Smith
  • Nick J Reynolds

Abstract

The quality of life (QoL) of psoriasis patients receiving biologic therapies in the "real-world" is relatively unknown. We assessed the impact of biologics on QoL & studied potential predictors for improved QoL, using a cohort of 2152 psoriasis patients (adalimumab (n=1239), etanercept (n=517) & ustekinumab (n=396); 81% were biologic-naïve) registered with the British Association of Dermatologists Biologic Interventions Register & followed-up for ≥6-months. Changes in QoL were assessed using the Dermatology Life Quality Index (DLQI) & EuroQoL-5D (EQ5D) at 6 & 12-months. For the entire cohort, the median (interquartile range) DLQI & EQ5D utility score improved from 18(13-24) & 0.7(0.6-0.8) at baseline to 2(0-7) & 0.9(0.7-1.0) at 6-months (p<0.0001), respectively; 46% & 54% of patients achieved a DLQI of 0/1 & a clinically meaningful change of ≥0.05 in their EQ5D. Improvements were generally maintained at 12-months. At 6-months the multivariable regression models showed that patients who were obese, with multiple comorbidities, & with lower QoL at baseline were significantly less likely to show either EQ5D improvements or achieve a DLQI of 0/1. As compared with adalimumab, patients on etanercept were less likely to achieve a DLQI of 0/1, however, there was no significant difference between the three biologics in improvement in EQ5D. Age, smoking & psoriatic arthritis were determinants of poor improvement in EQ5D. Similar factors were associated with QoL improvement at 12-months. In routine clinical practice, biologics were associated with improvement in QoL in psoriasis patients. The results of this study will help to inform clinical decisions in psoriasis management.

Bibliographical metadata

Original languageEnglish
Title of host publicationJournal of Investigative Dermatology
PagesS161-S294
Volume136
EditionIssue 9, Supplement 2
DOIs
Publication statusPublished - Sep 2016
EventEuropean Society for Dermatological Research - Technical University of Munich (TUM), Department of Mechanical Engineering, Munich, Germany
Event duration: 7 Sep 201610 Sep 2016
Conference number: 46th

Conference

ConferenceEuropean Society for Dermatological Research
Abbreviated titleESDR
CountryGermany
CityMunich
Period7/09/1610/09/16